ANIK - Anika Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.74
+0.21 (+0.63%)
As of 11:31AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close33.53
Open33.65
Bid33.67 x 1000
Ask33.83 x 1000
Day's Range33.12 - 34.17
52 Week Range22.01 - 75.72
Volume24,837
Avg. Volume193,293
Market Cap479.186M
Beta (5Y Monthly)1.18
PE Ratio (TTM)18.54
EPS (TTM)1.82
Earnings DateMay 22, 2020 - May 23, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-17% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Anika to Participate in 2020 UBS Virtual Global Healthcare Conference
    Business Wire

    Anika to Participate in 2020 UBS Virtual Global Healthcare Conference

    Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company, today announced that Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will present at the 2020 UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 8:20 a.m. ET.

  • Anika Therapeutics Inc (ANIK) Q1 2020 Earnings Call Transcript
    Motley Fool

    Anika Therapeutics Inc (ANIK) Q1 2020 Earnings Call Transcript

    With me on the call today is Dr. Cheryl Blanchard, who was recently appointed President and Chief Executive Officer of Anika. During today's call, Cheryl and I will review our first quarter 2020 financial results and key business highlights, which were summarized in our earnings release issued today.

  • Anika (ANIK) Moves to Buy: Rationale Behind the Upgrade
    Zacks

    Anika (ANIK) Moves to Buy: Rationale Behind the Upgrade

    Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • GlobeNewswire

    Anika Reports First Quarter 2020 Financial Results

    Total Revenue Increases 43% Year-over-YearContinued Progress on Integration of Parcus Medical and Arthrosurface AcquisitionsWithdrawing Full Year 2020 Financial Guidance Well.

  • Does Anika Therapeutics, Inc. (NASDAQ:ANIK) Have A High Beta?
    Simply Wall St.

    Does Anika Therapeutics, Inc. (NASDAQ:ANIK) Have A High Beta?

    Anyone researching Anika Therapeutics, Inc. (NASDAQ:ANIK) might want to consider the historical volatility of the...

  • Anika Therapeutics (ANIK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks

    Anika Therapeutics (ANIK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?
    Zacks

    ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?

    ANIK vs. ALKS: Which Stock Is the Better Value Option?

  • Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer
    Business Wire

    Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer

    Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced that Cheryl R. Blanchard, Ph.D., has been named President and Chief Executive Officer, effective April 26,2020. Dr. Blanchard has served as interim Chief Executive Officer of Anika since February 2020 and as a member of the Company’s Board of Directors since August 2018. Dr. Blanchard has more than 25 years of executive management experience with deep expertise in orthopedic medical devices, regenerative medicine and drug delivery.

  • Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7
    Business Wire

    Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7

    Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first quarter 2020 financial results after the close of the market on Thursday, May 7, 2020 and hold its investor conference call on the same day, Thursday, May 7, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.

  • GlobeNewswire

    Anika Takes Actions to Strengthen Liquidity in Light of COVID-19

    Anika Therapeutics, Inc. (ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (“HA”) technology platform, today provided an update on actions it is taking to strengthen liquidity in light of the COVID-19 pandemic. To strengthen its financial position, the Company is drawing down $50 million on its existing credit facility. Following the drawdown, the Company will have total liquidity of approximately $140 million, comprised of cash and investments on hand.

  • 3 Benjamin Graham-Style Stocks
    GuruFocus.com

    3 Benjamin Graham-Style Stocks

    These picks have a Graham blended multiplier below 22.5 Continue reading...

  • How Does Anika Therapeutics's (NASDAQ:ANIK) P/E Compare To Its Industry, After The Share Price Drop?
    Simply Wall St.

    How Does Anika Therapeutics's (NASDAQ:ANIK) P/E Compare To Its Industry, After The Share Price Drop?

    To the annoyance of some shareholders, Anika Therapeutics (NASDAQ:ANIK) shares are down a considerable 32% in the last...

  • Can You Imagine How Anika Therapeutics's (NASDAQ:ANIK) Shareholders Feel About The 29% Share Price Increase?
    Simply Wall St.

    Can You Imagine How Anika Therapeutics's (NASDAQ:ANIK) Shareholders Feel About The 29% Share Price Increase?

    Anika Therapeutics, Inc. (NASDAQ:ANIK) shareholders might be concerned after seeing the share price drop 29% in the...

  • Anika Appoints David Colleran as General Counsel
    Business Wire

    Anika Appoints David Colleran as General Counsel

    Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced the appointment of David Colleran to the newly created position of Executive Vice President, General Counsel and Corporate Secretary. In this new role, Mr. Colleran will lead the Company’s global legal organization, including corporate governance and compliance.

  • New Strong Sell Stocks for February 27th
    Zacks

    New Strong Sell Stocks for February 27th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • Benzinga

    The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...

  • Anika Therapeutics (ANIK) Beats Q4 Earnings and Revenue Estimates
    Zacks

    Anika Therapeutics (ANIK) Beats Q4 Earnings and Revenue Estimates

    Anika (ANIK) delivered earnings and revenue surprises of 4.88% and 7.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Anika Reports Fourth Quarter and Full Year 2019 Financial Results

    Total Revenue Increases 10% Year-over-Year for the Fourth QuarterCompletes Acquisitions of Parcus Medical and ArthrosurfaceCompany Expects Total Revenue Growth in the 40% to 44%.

  • Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for

    Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO

    Anika Therapeutics, Inc. (ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its search to identify a new CEO following the recent passing of Joseph Darling. In connection with Dr. Blanchard’s appointment, the previously announced interim Office of the President has been dissolved. “We are pleased that Dr. Blanchard, a seasoned executive who has previously served as a biotech President and CEO, has agreed to step in as our interim CEO as we search for Anika’s next leader,” said Dr. Joseph Bower, Chairman of Anika's Board of Directors.

  • Do You Like Anika Therapeutics, Inc. (NASDAQ:ANIK) At This P/E Ratio?
    Simply Wall St.

    Do You Like Anika Therapeutics, Inc. (NASDAQ:ANIK) At This P/E Ratio?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...

  • GlobeNewswire

    Anika Therapeutics Closes Acquisition of Arthrosurface

    Anika Therapeutics, Inc. (ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has completed its acquisition of Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active patients. Under the previously disclosed terms of the agreement, Anika acquired all outstanding shares of Arthrosurface in exchange for an upfront payment of approximately $60 million in cash from the company’s existing balance sheet, subject to customary closing adjustments. Arthrosurface shareholders will be eligible to receive an additional $40 million contingent upon the achievement of certain regulatory and commercial milestones.

  • GlobeNewswire

    Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer

    Anika Therapeutics, Inc. (ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away unexpectedly on January 29, 2020 in Upstate New York. “We are shocked and greatly saddened by the passing of Joe Darling,” said Joseph Bower, Chairman of Anika's Board of Directors. On behalf of the Board of Directors and all Anika employees, as well as the many people he worked with and mentored over the years, we would like to extend our deepest condolences to the Darling family, including his wife, Maureen, and children, Jon and Jordan.

  • GlobeNewswire

    Anika Therapeutics Closes Acquisition of Parcus Medical

    BEDFORD, Mass., Jan. 24, 2020 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging.

  • Sale of Global Leader in Joint Preservation Incubated at Primo Medical Group
    PR Newswire

    Sale of Global Leader in Joint Preservation Incubated at Primo Medical Group

    Primo Medical Group, a Massachusetts based medical device manufacturer and incubator, is pleased to announce the sale of its spin-off company Arthrosurface, to Anika Therapeutics.